Recruiting NA 22Q11 Deletion Syndrome

New treatment option for 22Q11 Deletion Syndrome

Official title Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome

ClinicalTrials.gov ID: NCT05664412

What this study is testing

What it's testing
The purpose of this project is to explore the effects of transcranial alternating current stimulation (tACS) in children, adolescents and young adults with a 22q11.2 microdeletion. The main aim of the present research project is to investigate the effects of repeated, individually tuned high-density (HD) tACS on cognition (i.e., WM performance) and related neuroimaging markers in carriers of the 22q11DS.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 14 to 25

You may be able to join if

  • Confirmed genetic diagnosis of 22q11DS
  • Age between 14 and 25 years old
  • Willingness to participate
  • Informed Consent signed by the subject and/or the caregiver(s)

You likely can't join if

  • Epilepsy
  • Deep brain stimulation electrodes
  • Traumatic brain injury
  • Facial metal implants

The study team makes the final eligibility decision.

Where it's taking place

  • Geneva, Canton of Geneva, Switzerland

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 14 years to 25 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Geneva, Canton of Geneva, Switzerland. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.